JP2014505264A5 - - Google Patents

Download PDF

Info

Publication number
JP2014505264A5
JP2014505264A5 JP2013553610A JP2013553610A JP2014505264A5 JP 2014505264 A5 JP2014505264 A5 JP 2014505264A5 JP 2013553610 A JP2013553610 A JP 2013553610A JP 2013553610 A JP2013553610 A JP 2013553610A JP 2014505264 A5 JP2014505264 A5 JP 2014505264A5
Authority
JP
Japan
Prior art keywords
marker
level
determining
biological sample
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013553610A
Other languages
English (en)
Japanese (ja)
Other versions
JP5990542B2 (ja
JP2014505264A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/024729 external-priority patent/WO2012109592A1/en
Publication of JP2014505264A publication Critical patent/JP2014505264A/ja
Publication of JP2014505264A5 publication Critical patent/JP2014505264A5/ja
Application granted granted Critical
Publication of JP5990542B2 publication Critical patent/JP5990542B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013553610A 2011-02-11 2012-02-10 全身性エリテマトーデスのリスクスコアを算出する方法 Expired - Fee Related JP5990542B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161441785P 2011-02-11 2011-02-11
US61/441,785 2011-02-11
US201161442454P 2011-02-14 2011-02-14
US61/442,454 2011-02-14
US201161472424P 2011-04-06 2011-04-06
US61/472,424 2011-04-06
PCT/US2012/024729 WO2012109592A1 (en) 2011-02-11 2012-02-10 Methods for diagnosing systemic lupus erythematosus

Publications (3)

Publication Number Publication Date
JP2014505264A JP2014505264A (ja) 2014-02-27
JP2014505264A5 true JP2014505264A5 (enExample) 2015-04-02
JP5990542B2 JP5990542B2 (ja) 2016-09-14

Family

ID=45774332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013553610A Expired - Fee Related JP5990542B2 (ja) 2011-02-11 2012-02-10 全身性エリテマトーデスのリスクスコアを算出する方法

Country Status (4)

Country Link
US (6) US10132813B2 (enExample)
EP (1) EP2673644B1 (enExample)
JP (1) JP5990542B2 (enExample)
WO (1) WO2012109592A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2673644B1 (en) * 2011-02-11 2016-02-10 Exagen Diagnostics, Inc. Methods for diagnosing systemic lupus erythematosus
WO2014093268A1 (en) * 2012-12-10 2014-06-19 Allegheny-Singer Research Institute Methods and systems for using complement-tagged molecules as biomarkers of disease
US9863946B2 (en) 2013-02-08 2018-01-09 Allegheny-Singer Research Institute Cell-bound complement activation products as diagnostic biomarkers for pre-lupus
JP6400604B2 (ja) 2013-02-08 2018-10-03 アレゲーニー・シンガー リサーチ インスティチュート プレループス診断用バイオマーカーとしての細胞結合性補体活性産物
CN105229470B (zh) * 2013-03-15 2018-11-27 艾克斯肯诊断股份有限公司 用于治疗和诊断系统性红斑狼疮的方法
WO2014193611A1 (en) * 2013-05-29 2014-12-04 Oklahoma Medical Research Foundation Bright/arid3a function/expression as a marker for systemic lupus erythematosus severity and intensity
US20170074876A1 (en) * 2014-03-13 2017-03-16 INSERM (Institut National de la Sante et da la Recherche Medicale) Diagnosis Method for Lupus
BR112017002575B1 (pt) * 2014-08-08 2023-11-07 Allegheny Singer Research Institute Método para diagnosticar especificamente lúpus sistêmico eritematoso em um indivíduo
IL256399B (en) 2015-06-19 2022-09-01 Sera Prognostics Inc Biomarker pairs for predicting preterm birth
JP6674543B2 (ja) * 2015-07-31 2020-04-01 アレゲーニー・シンガー リサーチ インスティチュート 抗体に基づく薬物のコンパニオン診断としての細胞結合補体活性化産物アッセイ
EP4217744A4 (en) * 2020-09-28 2024-11-06 Allegheny Singer Research Institute METHOD FOR DETERMINING A LEVEL OF A CELL FRAGMENT-BOUND COMPLEMENT ACTIVATION PRODUCT
KR102608933B1 (ko) * 2021-10-20 2023-12-01 재단법인 아산사회복지재단 전신 홍반성 루푸스 환자의 루푸스 신염 진단용 바이오마커 조성물 및 이를 이용한 루푸스 신염 진단에 필요한 정보를 제공하는 방법
CN119889651B (zh) * 2024-12-24 2025-11-18 北京医院 一种基于流式细胞术的系统性红斑狼疮评估模型的构建方法及系统性红斑狼疮评估方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256708B2 (en) 1999-06-23 2007-08-14 Visicu, Inc. Telecommunications network for remote patient monitoring
DE60237529D1 (de) * 2001-09-10 2010-10-14 Univ Pittsburgh Diagnose und aufzeichnung von systemischem lupus erythematosus und von skleroderm
JP4550051B2 (ja) 2003-04-16 2010-09-22 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 全身性エリテマトーデスの同定およびモニタリング
KR20060015646A (ko) 2003-06-13 2006-02-17 유니버시티 오브 피츠버그 면역, 혈액 및 염증성 질환의 모니터링 방법
DK1756571T3 (da) 2004-04-09 2010-12-13 Univ Pittsburgh Fremgangsmåde i realtid til detektering af akut inflammatoriske tilstande
AU2005242719B2 (en) * 2004-05-11 2011-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Diagnosing and monitoring inflammatory diseases by measuring complement components on white blood cells
US20060105419A1 (en) * 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
US20070148704A1 (en) * 2005-10-06 2007-06-28 Ursula Klause Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
EP2008213A1 (en) * 2006-04-07 2008-12-31 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Systems and methods for predicting an individual's risk of developing rheumatoid arthritus
CA2738952A1 (en) 2008-10-16 2010-04-22 Cypress Bioscience, Inc. Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (sle) and other autoimmune diseases
WO2011047337A2 (en) * 2009-10-16 2011-04-21 Exagen Diagnostics, Inc. Cell-based complement activation product algorithm for diagnosing systemic lupus erythematosus
EP2336769A1 (en) 2009-12-18 2011-06-22 F. Hoffmann-La Roche AG Trigger assay for differentiating between rheumatic and non-rheumatic disorders
ES2425540T3 (es) 2010-02-22 2013-10-16 Medipan Gmbh Procedimiento y dispositivo para la detección simultánea de anticuerpos unidos a sustratos sintéticos y celulares y/o tisulares
EP2673644B1 (en) 2011-02-11 2016-02-10 Exagen Diagnostics, Inc. Methods for diagnosing systemic lupus erythematosus
WO2013134431A1 (en) 2012-03-06 2013-09-12 Life Technologies Corporation Biomarkers for systemic lupus erythematosus
CN105229470B (zh) 2013-03-15 2018-11-27 艾克斯肯诊断股份有限公司 用于治疗和诊断系统性红斑狼疮的方法

Similar Documents

Publication Publication Date Title
JP2014505264A5 (enExample)
Kumar et al. Density-based separation in multiphase systems provides a simple method to identify sickle cell disease
US11600373B2 (en) Biodosimetry panels and methods
Hu et al. Red blood cell distribution width is a potential index to assess the disease activity of systemic lupus erythematosus
Kay et al. ACR/EULAR 2010 rheumatoid arthritis classification criteria
Bizzaro et al. Are we at a stage to predict autoimmune rheumatic diseases?
Jansen et al. IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities
Rahman et al. Development and validation of an early scoring system for prediction of disease severity in COVID-19 using complete blood count parameters
Walzl et al. Biomarkers for TB treatment response: challenges and future strategies
Grauer et al. Neurocognitive decline in HIV patients is associated with ongoing T‐cell activation in the cerebrospinal fluid
Kaziz et al. Taguchi optimization of integrated flow microfluidic biosensor for COVID-19 detection
Paczesny Post‐haematopoietic cell transplantation outcomes: why ST2 became a ‘golden nugget’biomarker
Loga et al. Relevant biomarkers of kidney allograft rejection
JP2017528734A5 (enExample)
CN119889651B (zh) 一种基于流式细胞术的系统性红斑狼疮评估模型的构建方法及系统性红斑狼疮评估方法
Manolis et al. The European Medicines Agency experience with biomarker qualification
Barnes et al. Use of blood based biomarkers in the evaluation of Crohn’s disease and ulcerative colitis
RU2017107273A (ru) Антилимфоцитарные аутоантитела в качестве диагностических биомаркеров
Heikal et al. Immune function surveillance: association with rejection, infection and cardiac allograft vasculopathy
Ye et al. Adenosine deaminase as a potential diagnostic and prognostic biomarker for severe fever with thrombocytopenia syndrome
Quismorio Jr et al. Clinical application of serologic tests, serum protein abnormalities, and other clinical laboratory tests in systemic lupus erythematosus
Wicks et al. T lymphocyte phenotype of contact‐allergic patients: experience with nickel and p‐phenylenediamine
Boin et al. Evaluation of topoisomerase‐1‐specific CD8+ T‐cell response in systemic sclerosis
Deane Learning about the natural history of rheumatoid arthritis development through prospective study of subjects at high risk of rheumatoid arthritis–related autoimmunity
Ahearn et al. The lupus biomarker odyssey: one experience